Is Catalyst Pharmaceuticals, Inc. (CPRX) a Buy, Sell, or Hold?
Catalyst Pharmaceuticals, Inc.
NASDAQ:CPRX
$31.49 USD
$0 (0.0%)
- Volume
- 15.51M
- Average Volume
- 2.67M
- Market Capitalization
- $3.85B
- P/E Ratio
- 17.49
- Dividend Yield
- 0.00%
- Price Target
- $31.75
- Year High
- $32.56
- Year Low
- $19.05
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $7.10
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Richard John Daly |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | CPRX |
| CUSIP | 14888U101 |
| CIK | 0001369568 |
| Web | https://www.catalystpharma.com |
| Phone | 305 420 3200 |
| Currency | USD |
| Employees | 182 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 7.10 |
| Quick Ratio | 6.84 |
| Cash Ratio | 5.71 |
Sales & Book Value
| Annual Sales | $588.99M |
| Price / Sales | 6.46 |
| Cash Flow | 1.70 |
| Price / Cash Flow | 18.52 |
| Price / Book | 3.80 |
Price Target and Rating
| Average Stock Price Forecast | $31.75 |
| High Stock Price Forecast | $32.00 |
| Low Stock Price Forecast | $31.50 |
| Forecast Upside/Downside | -0.82% |
| Consensus Rating | Buy |
| Rating Score(0-5) | 4 |
| Research Coverage | 16 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $1.68 |
| Trailing P/E Ratio | 17.49 |
| PEG Ratio | 2.07 |
| P/E Growth | 2.07 |
| Net Income | $214.33M |
| Net Margin | 37.08% |
| Pretax Margin | 49.66% |
| Return on Equity | 23.65% |
| Return on Assets | 19.29% |
Financials Score
| AltmanZ Score | 19.99 |
| Piotroski Score | 4.00 |
| Working Capital | 807.99M |
| Total Assets | 1.15B |
| Ebit | 296.46M |
| Market Cap | 3.85B |
| Total Liabilities | 134.91M |
Poll Results
About Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock
Catalyst Pharmaceuticals, Inc., founded in 2002 and based in Coral Gables, Florida, operates as a commercial-stage biopharmaceutical enterprise. This company is dedicated to discovering, developing, and marketing therapeutic solutions for individuals in the United States who are afflicted with uncommon, severe, and long-term neuromuscular and neurological disorders. Among its key offerings is Firdapse, an amifampridine phosphate tablet formulation approved for managing Lambert-Eaton Myasthenic Syndrome (LEMS). Catalyst also provides Ruzurgi, a specific treatment option for pediatric patients diagnosed with LEMS. Beyond its existing products, Catalyst is actively investigating additional applications for Firdapse, including its potential use in treating MuSK antibody positive myasthenia gra ... vis, spinal muscular atrophy type 3, and hereditary neuropathy with liability to pressure palsies. The company engages in various strategic collaborations, such as licensing agreements with BioMarin Pharmaceutical Inc., and a joint development and commercialization agreement with Endo Ventures Limited concerning a generic version of Sabril tablets. Previously known as Catalyst Pharmaceutical Partners, Inc., the company adopted its current name in May 2015.
Catalyst Pharmaceuticals Stockholders Clear Angelini Pharma Merger
2026-07-10 06:03:39
Catalyst Pharmaceuticals NASDAQ: CPRX stockholders approved the company's proposed merger with Angelini Pharma S.p.A. at a special meeting held virtually on July 8, according to remarks from company officials during the meeting.
CPRX's Agamree Shows Potential Beyond DMD After Positive Phase I Data
2026-07-02 10:36:08
Catalyst Pharmaceuticals' Agamree matches Emflaza's glucocorticoid activity while showing less immunosuppression, supporting potential expansion into new rare disease indications.
2026-06-30 08:03:00
Data Demonstrate Vamorolone's Balanced Corticosteroid Profile with On-Target Glucocorticoid Activity and Without Evidence of Significant Immunosuppressive Activity at Clinical Doses Data Demonstrate Vamorolone's Balanced Corticosteroid Profile with On-Target Glucocorticoid Activity and Without Evidence of Significant Immunosuppressive Activity at Clinical Doses
Are NUVL, CPRX, TMHC Obtaining Fair Deals for their Shareholders?
2026-06-25 13:00:00
Are NUVL, CPRX, TMHC Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 25, 2026
2026-06-24 15:00:00
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of [url="]Kahn Swick and Foti[/url], LLC (âKSFâ) are investigating the propo
2026-06-24 14:38:00
NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Catalyst Pharmaceuticals, Inc. (NasdaqCM: CPRX) to Angelini Pharma S.p.A. Under the terms of the proposed transaction, shareholders of Catalyst will receive $31.50 in cash for each share of Catalyst that they own. KSF is seeking to determine whether this consideration and the process that led t.
Catalyst (CPRX) Up 0.6% Since Last Earnings Report: Can It Continue?
2026-06-10 12:31:13
Catalyst (CPRX) reported earnings 30 days ago. What's next for the stock?
Why Catalyst Pharmaceutical (CPRX) is a Top Momentum Stock for the Long-Term
2026-05-27 10:50:23
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Frequently Asked Questions
-
What is the current Catalyst Pharmaceuticals, Inc. (CPRX) stock price?
-
Catalyst Pharmaceuticals, Inc.(NASDAQ:CPRX) stock price is $31.49 in the last trading session. During the trading session, CPRX stock reached the peak price of $32.56 while $19.05 was the lowest point it dropped to. The percentage change in CPRX stock occurred in the recent session was 0.0% while the dollar amount for the price change in CPRX stock was $0.
-
CPRX's industry and sector of operation?
-
The NASDAQ listed CPRX is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of CPRX?
-
Michael W. Kalb | Executive Vice President, Treasurer & Chief Financial Officer
Preethi Sundaram | Chief Strategy Officer
Steven R. Miller | Executive Vice President, Chief Operating Officer & Chief Scientific Officer
Jeffrey Del Carmen | Executive Vice President & Chief Commercial Officer
William T. Andrews FACP | Chief Medical Officer -
How many employees does CPRX have?
-
Number of CPRX employees currently stands at 182. CPRX operates from 355 Alhambra Circle, Coral Gables, FL 33134, US.
-
Link for CPRX official website?
-
Official Website of CPRX is: https://www.catalystpharma.com
-
How do I contact CPRX?
-
CPRX could be contacted at phone #305 420 3200 and can also be accessed through its website. CPRX operates from 355 Alhambra Circle, Coral Gables, FL 33134, US.
-
How many shares of CPRX are traded daily?
-
The average number of CPRX shares traded daily for last 3 months was 2.67M.
-
What is the market cap of CPRX currently?
-
The market value of CPRX currently stands at $3.85B with its latest stock price at $31.49